- Home
- LTRN vs COCH Comparison
LTRN vs COCH Comparison
Compare LTRN & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LTRN | COCH |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 24.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LTRN | COCH |
|---|---|---|
| Price | $3.31 | $0.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $25.00 | $9.50 |
| AVG Volume (30 Days) | 73.5K | ★ 434.7K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $208,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.55 | $0.64 |
| 52 Week High | $6.12 | $2.00 |
Technical Indicators
Market Signals| Indicator | LTRN | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 39.97 |
| Support Level | $3.19 | $0.80 |
| Resistance Level | $3.49 | $0.77 |
| Average True Range (ATR) | 0.26 | 0.05 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 9.88 | 25.13 |
Price Performance
Historical ComparisonAbout LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.